Actively Recruiting
Geranylgeraniol Supplementation in Patients With Mevalonate Kinase Deficiency
Led by University Hospital, Motol · Updated on 2024-07-12
6
Participants Needed
1
Research Sites
205 weeks
Total Duration
On this page
Sponsors
U
University Hospital, Motol
Lead Sponsor
W
Washington University School of Medicine
Collaborating Sponsor
AI-Summary
What this Trial Is About
Mevalonate kinase deficiency (HyperIgD syndrome, HIDS) is an inborn error of immunity caused by a block in the mevalonate pathway. The subsequent lack of isoprenoids with antiinflammatory properties might contribute to the autoinflammatory nature of the disease. A pilot study aims to verify the safety and efficacy of the dietary supplement Geranylgeraniol, aiming at a mitigation of isoprenoids deficiency caused by the above-mentioned block in the MVK pathway.
CONDITIONS
Official Title
Geranylgeraniol Supplementation in Patients With Mevalonate Kinase Deficiency
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients older than 12 years with genetically confirmed MVK deficiency
- Overall good clinical status apart from the clinical presentation of the MVK deficiency
- Normal liver tests
- Compliance with the study protocol
You will not qualify if you...
- Children below 12 years
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University Hospital, Motol
Prague, Czechia, 15006
Actively Recruiting
Research Team
A
Anna Šedivá, Prof
CONTACT
E
Eva Aljamal, Mgr
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here